Storage and handling
STORE IN A COOL PLACE KEEP BAG TIGHTLY CLOSED
STORE IN A COOL PLACE KEEP BAG TIGHTLY CLOSED
Approved by the FDA under NADA # 034-393
COYDEN® 25%
(clopidol)
Type A Medicated Article
ACTIVE DRUG INGREDIENT: Clopidol.................................113.5 gm/lb (25%)
INGREDIENTS: Rice Hulls, Mineral Oil, Fatty Acid Glycerides
BROILER/REPLACEMENT CHICKENS:
As an aid in the prevention of cecal and intestinal cocciodiosis caused by E. tenella, E. necatrix,
E. acervulina, E. maxima, E. brunetti, E. mivati.
TURKEYS:
As an aid in the prevention of leucocytozoonosis caused by Leucocytozoon smithi.
SEE DIRECTIONS ON BACK PANEL
FOR THE MANUFACTURE OF COMPLETE FEEDS ONLY.
Manufactured by:
HUVEPHARMA, Inc. Peachtree City, GA 30269 Huvepharma, Inc.
525 Westpark Drive, Suite 230
Distributed by: Peachtree City, GA 30269
HUVEPHARMA, Inc. Peachtree City, GA 30269
For questions, call 1-877-994-4883
® COYDEN is a registered trademark of Huvepharma, Inc.
Net Wt.: 50 lb (22.68 kg)
INDICATIONS FOR USE:
BROILER AND REPLACEMENT CHICKENS
As an aid in the prevention of coccidiosis in broilers and replacements for caged layers caused by
E. tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, E. mivati.
TURKEYS GROWN FOR MEAT PURPOSES ONLY
As an aid in the prevention of leucocytozoonosis caused by Leucocytozoon smithi.
USER SAFETY WARNING:
Not for Human Use. Keep Out of Reach of Children.
Contact Huvepharma Inc. at 1-877-994-4883 or
www.huvepharma.us. For additional
information about reporting side effects for animal drugs, contact FDA at 1-888-FDA-VETS or
www.fda.gov/reportanimalae.
WITHDRAWAL PERIODS AND RESIDUE WARNINGS:
CHICKENS: When feeding 0.025% clopidol, reduce dosage to 0.0125% or withdraw
medication 5 days before slaughter. Do not feed to chickens over 16 weeks of age.
TURKEYS: Withdraw medication 5 days before slaughter.
CAUTION: Consult a veterinarian or poultry pathologist if losses exceed 0.5% in a 2-day period.
MIXING DIRECTIONS:
For Complete Rations - Type C Medicated Products
COYDEN® 25% (clopidol) should be thoroughly and evenly mixed in the feed in accordance with
current good manufacturing practice for medicated feed. COYDEN 25% may be used to manufacture
a Type C medicated feed in the concentration range of 0.0125% to 0.025% clopidol.
To aid in even distribution of COYDEN 25% in the finished feed, prepare a mixture of COYDEN 25% in
a portion of complete feed ingredient before mixing into the finished ration. Blend the mixture with
the remainder of the finished feed and mix thoroughly.
DIRECTIONS FOR USE:
Must be mixed with other ingredients before feeding.
Mixing and conveying equipment should be properly grounded.
Use 1 pound of COYDEN 25% per ton of feed to produce a feed containing 0.0125% clopidol.
Use 2 pounds of COYDEN 25% per ton of feed to produce a feed containing 0.025% clopidol.
FEEDING DIRECTIONS:
Feed continuously, as the sole ration, either the 0.0125% or 0.025% Type C medicated feed
depending upon management practices, degree of exposure, and amount of feed eaten.
STORE IN A COOL PLACE
KEEP BAG TIGHTLY CLOSED
Restricted Drug (California)
Use only as Directed
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 23243-9568-5 | CoydenType A Medicated Article | 22.68 kg in 1 BAG | POWDER | 22.68 | 5 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 23243-9568 | COYDEN TYPE A MEDICATED ARTICLE (CLOPIDOL) POWDER [HUVEPHARMA, INC.] | 5 | 1 package rows | 20240510_28e3ce6c-fb4a-45a9-bd1d-74b1c61005b7.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CLOPIDOL | ACTIVE INGREDIENT | 8J763HFF5N | 1 | |
| CLOPIDOL | ACTIVE MOIETY | 8J763HFF5N | 1 | |
| MINERAL OIL | INACTIVE INGREDIENT | T5L8T28FGP | 1 | |
| RICE BRAN | INACTIVE INGREDIENT | R60QEP13IC | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 23243-9568 | 23243-9568-5 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| CLOPIDOL | 8J763HFF5N | ACTIB |
| MINERAL OIL | T5L8T28FGP | IACT |
| RICE BRAN | R60QEP13IC | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | GEL / TOPICAL | 2.5 %w/w | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | OINTMENT / OPHTHALMIC | 59.5 %w/w | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | CAPSULE / ORAL | 120 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | TABLET, DELAYED RELEASE / ORAL | 5.67 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | TABLET, CHEWABLE / ORAL | 6 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | OINTMENT / TOPICAL | 9938 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | TABLET, COATED / ORAL | 1.5 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | SYSTEM / TRANSDERMAL | 6.09 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | LOTION / TOPICAL | 1428 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | SUPPOSITORY / VAGINAL | 30 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | PASTE / DENTAL | 95 %w/w | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | TABLET, FILM COATED / ORAL | NA | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | SUSPENSION / OPHTHALMIC | 0.1 %w/w | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | SYSTEM / TOPICAL | 654.36 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | FILM, EXTENDED RELEASE / TRANSDERMAL | 34 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | SUPPOSITORY / RECTAL | NA | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | SUSPENSION / AURICULAR (OTIC) | 0.5 %w/v | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | TABLET, EXTENDED RELEASE / ORAL | NA | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | CREAM / TOPICAL | 2772 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | SPRAY / TOPICAL | 1379 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | CREAM / VAGINAL | 402 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | OIL / TOPICAL | 43.29 %v/v | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | SOAP / TOPICAL | 0.82 %w/w | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | OINTMENT / AURICULAR (OTIC) | NA | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | PASTE / TOPICAL | 47.5 %w/w | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | DROPS / ORAL | NA | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | SUSPENSION / TOPICAL | 82 %w/w | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | FILM / TRANSDERMAL | 11.42 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | TABLET / ORAL | 113.75 mg |
Adverse event summaries are temporarily unavailable. Other product information remains available.